<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR1800015259</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2018-03-19</date_registration>
      <primary_sponsor>ZhongDa Hospital Southeast University </primary_sponsor>
      <public_title>Clinical study of cord blood transplantation with modified and dose-reduced BUCY regimen on the treatment of hematological malignancies</public_title>
      <acronym />
      <scientific_title>Clinical study of cord blood transplantation with modified and dose-reduced BUCY regimen on the treatment of hematological malignancies</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-03-20</date_enrolment>
      <type_enrolment />
      <target_size>Case series:75;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=25644</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>malignant hematological disease </hc_freetext>
      <i_freetext>Case series:modified and dose-reduced BUCY;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Ding Jiahua</firstname>
        <middlename />
        <lastname />
        <address>87-1 Ding jiaqiao Road, Gulou District, Nanjing, Jiangsu, China</address>
        <city />
        <country1 />
        <zip>210009</zip>
        <telephone>+86 13809027048</telephone>
        <email>973092642@qq.com</email>
        <affiliation>Zhongda Hospital Southeast University  </affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Ding Jiahua</firstname>
        <middlename />
        <lastname />
        <address>87-1 Ding jiaqiao Road, Gulou District, Nanjing, Jiangsu, China </address>
        <city />
        <country1 />
        <zip>210009</zip>
        <telephone>+86 13809027048</telephone>
        <email>973092642@qq.com</email>
        <affiliation>Zhongda Hospital Southeast University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>(1) aged 2 to 65 years;
(2) absence a HLA-matched sibling donor, and/or in need of an urgent allograft;
(3) at freezing, nucleated cell dose should be&gt;2.5x107/kg and CD34 cell dose &gt;1.2x105/kg; if the cell dose was insufficient with a single CBU, double cord blood unit was used;
(4) the score of Karnofsky â‰¥60;
(5) Signed written informed consent. </inclusion_criteria>
      <agemin>2</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>(1) Serious viscera dysfunction or disease, such as serious diseases and function disorder in heart, liver, kidney and pancreas;
(2) Patients with pregnancy;
(3) Participants and/or authorized family members refused to accept UCBT;
(4) Researchers believe that can damage the unnecessary risks to safety, make the results of the study subjects any life-threatening illness, condition or organ system dysfunction; drug dependence; uncontrolled mental disease; cognitive impairment;
(5) Researchers think that the patient doesn't fit into the study. </exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cumulative rate of neutrophil engraftment;Cumulative rate of platelet engraftment;Overall survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>GVHD;chimerism;relapse;TRM;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-financing</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-05-11</approval_date>
        <contact_name>Ming Chen</contact_name>
        <contact_address>87-1 Ding jiaqiao Road, Gulou District, Nanjing, Jiangsu, China</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>